☆ 3.9 Review

Updated systematic review and meta-analysis of extended adjuvant temozolomide in patients with newly diagnosed glioblastoma

NEURO-ONCOLOGY ADVANCES (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

A critical analysis of neuro-oncology clinical trials

Yeonju Kim et al.

Summary: Limitations in trial design, accrual, and data reporting hinder efficient and reliable drug evaluation in cancer clinical trials. A semi-automated survey of adult interventional neuro-oncology trials revealed suboptimal trial designs with low randomization rates and overestimation of effect size. Limited results reporting calls for incentives to improve data reporting and harmonization.

NEURO-ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Impact of Extended Adjuvant Temozolamide Beyond 6 Months in the Management of Glioblastoma Patients

Rasha Elsaka et al.

Summary: The study aimed to evaluate the benefits of prolonging adjuvant temozolomide (TMZ) therapy beyond 6 cycles in glioblastoma multiform patients. The medical records of 329 patients diagnosed with diffuse gliomas in 2 cancer centers in Egypt were reviewed. The results showed that extending adjuvant TMZ therapy beyond 6 cycles may significantly improve the progression-free survival and overall survival in patients with glioblastoma multiform.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2023)

添加到收藏夹

Review Oncology

Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement

Stephen J. Bagley et al.

Summary: This article reviews the limited therapeutic advances for glioblastoma and the failure of recent clinical trials, and emphasizes the need for improvement in clinical trial conduct. Challenges related to clinical trial eligibility criteria and trial design in glioblastoma are identified, and data-driven analysis of current glioblastoma clinical trials is provided.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Beyond standard data collection - the promise and potential of BRAIN (Brain tumour Registry Australia INnovation and translation registry)

Lucy Gately et al.

Summary: This article describes the design and implementation of the Australian brain cancer registry, BRAIN, which aims to support prospective studies and translational research in the field. Between February and December 2021, 350 new patients have been entered into BRAIN, with support for registry trials and a translational program in neuro-oncology.

BMC CANCER (2022)

添加到收藏夹

Article Oncology

Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis

Jingjing Wang et al.

Summary: This retrospective cohort study evaluated the survival outcomes of high-grade glioma patients treated with standard radiotherapy and temozolomide (TMZ). The results showed that prolonging adjuvant TMZ treatment beyond six cycles improved progression-free survival and overall survival. Patients with wild-type IDH and MGMT promoter methylation had a better response to extended treatment.

JOURNAL OF NEURO-ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study

Jie Chen et al.

Summary: This study suggests that extended adjuvant temozolomide treatment can significantly improve the prognosis of newly diagnosed glioblastoma patients, regardless of p53 mutation status. The effect of this treatment also varies among patients with different MGMT methylation, IDH1 mutation, and Ki67 expression levels.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Oncology

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019

Quinn T. Ostrom et al.

Summary: The report provides the latest data on primary brain tumors in the United States, including incidence rates, mortality rates, and relative survival rates. The overall incidence rate is higher in females and non-Hispanic population, and glioblastoma is the most common malignant brain tumor, while meningioma is the most common non-malignant brain tumor. The relative survival rate is lower for malignant brain tumors and higher for non-malignant brain tumors.

NEURO-ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma

Benjamin Y. Kong et al.

Summary: The MAGMA trial aims to test the effectiveness of different interventions designed to improve the survival rate of GBM patients. Newly diagnosed GBM patients are recruited to compare surgical resection followed by chemoradiotherapy with adjuvant chemotherapy alone or with additional neoadjuvant or extended chemotherapy.

BMJ OPEN (2022)

添加到收藏夹

Article Health Care Sciences & Services

Can Extended Chemotherapy Improve Glioblastoma Outcomes? A Retrospective Analysis of Survival in Real-World Patients

Natalia Gherasim-Morogai et al.

Summary: A retrospective analysis showed that extending the cycles of temozolomide chemotherapy can improve survival in patients with glioblastoma multiforme. Younger age, female gender, good performance status, absence of cognitive dysfunctions, no steroid use, and total tumor resection were prognostic factors associated with improved survival.

JOURNAL OF PERSONALIZED MEDICINE (2022)

添加到收藏夹

Article Clinical Neurology

Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival

Bin Huang et al.

Summary: In this study, the effects of standard 6 cycles versus > 6 cycles of temozolomide (TMZ) chemotherapy on survival of primary glioblastoma multiforme (GBM) patients were compared. The results showed that long-term adjuvant TMZ chemotherapy improved progression-free survival (PFS) and 2-year survival rate, while also enhancing quality of life, but did not significantly impact overall survival (OS).

BMC NEUROLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Extended dosing (12 cycles) vs. conventional dosing (6 cycles) of adjuvant temozolomide in adults with newly diagnosed high grade gliomas: A randomized, single-blind, two-arm, parallel-group controlled trial

S. A. Javadinia et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide

Rencui Quan et al.

MEDICINE (2020)

添加到收藏夹

Article Oncology

A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

Carmen Balana et al.

NEURO-ONCOLOGY (2020)

添加到收藏夹

Letter Oncology

Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less? Comment on A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

Tejpal Gupta et al.

NEURO-ONCOLOGY (2020)

添加到收藏夹

Article Clinical Neurology

Ongoing improvements in postoperative survival of glioblastoma in the temozolomide era: a population-based data linkage study

Amy Johnston et al.

NEURO-ONCOLOGY PRACTICE (2020)

添加到收藏夹

Article Oncology

The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review

Ehsan Alimohammadi et al.

ONCOLOGY REVIEWS (2020)

添加到收藏夹

Article Medicine, General & Internal

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial

Roger Stupp et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)

添加到收藏夹

Editorial Material Oncology

A search for the Goldilocks zone with regard to the optimal duration of adjuvant temozolomide in patients with glioblastoma

Stuart A. Grossman et al.

NEURO-ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG

Deborah T. Blumenthal et al.

NEURO-ONCOLOGY (2017)

添加到收藏夹

Article Clinical Neurology

Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma

Dorothee Gramatzki et al.

NEUROLOGY (2017)

添加到收藏夹

Article Oncology

Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma

Marco Skardelly et al.

ONCOLOGIST (2017)

添加到收藏夹

Article Clinical Neurology

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles

Giuseppe M. V. Barbagallo et al.

NEUROSURGICAL FOCUS (2014)

添加到收藏夹

Article Oncology

Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme

Gloria B. Roldan Urgoiti et al.

JOURNAL OF NEURO-ONCOLOGY (2012)

添加到收藏夹

Article Medicine, General & Internal

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Julian P. T. Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2011)

添加到收藏夹

Article Oncology

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Roger Stupp et al.

LANCET ONCOLOGY (2009)

添加到收藏夹

Article Medicine, General & Internal

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

David Moher et al.

BMJ-BRITISH MEDICAL JOURNAL (2009)

添加到收藏夹

Article Medicine, General & Internal

MGMT gene silencing and benefit from temozolomide in glioblastoma

ME Hegi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

添加到收藏夹

Article Medicine, General & Internal

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

R Stupp et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.